Your 5-Step Lab-to-Market Checklist for Biotech Product Success

Every year, promising biotech discoveries fail to reach patients or markets not because the science was wrong, but because the path from lab to market was mismanaged. Researchers pour years into a breakthrough, only to stumble on regulatory hurdles, manufacturing scale-up, or a business model that doesn't fit. This checklist is for the scientist who wants to think like a product developer, the entrepreneur who needs a roadmap, and the project manager looking for a repeatable process. We've distilled the journey into five steps that cover the essential decisions and actions from earliest validation through commercial launch. This is general information only; always consult regulatory and business professionals for your specific case.

Why This Matters Now: The Changing Biotech Landscape

The biotech industry is moving faster than ever. Investors, regulators, and patients expect quicker turnaround from discovery to approved product. Meanwhile, the cost of development continues to rise, and competition for funding and market share is intense. A well-structured lab-to-market plan is no longer a luxury—it's a survival tool.

Many projects fail at the translation step. A molecule that works perfectly in a petri dish may behave unpredictably in animals or humans. A process that works at the bench scale may be impossible to reproduce at commercial volumes. And even if the science holds, a product can fail because the company didn't secure intellectual property early, didn't understand the reimbursement landscape, or didn't build a manufacturing partnership in time. The stakes are high: according to industry analyses, only about one in ten drug candidates that enter clinical trials ultimately gain approval. For medical devices and diagnostics, the failure rate is lower but still significant.

This checklist addresses the most common failure points. It helps teams ask the right questions at the right time, allocate resources wisely, and avoid costly rework. The goal is not to guarantee success—no tool can do that—but to increase the odds by imposing discipline and foresight. Whether you are developing a novel therapeutic, a diagnostic test, or a biomanufacturing tool, the principles here apply.

Who Should Use This Checklist

This guide is designed for early-stage biotech teams: academic labs spinning out a company, startup founders with a scientific background, and product managers in established firms launching a new line. If you are at the point where you have a proof-of-concept and are considering next steps, this checklist can help you prioritize.

The Cost of Skipping Steps

Cutting corners to save time often backfires. For example, filing a provisional patent application without a thorough freedom-to-operate search can lead to expensive litigation later. Scaling up a process before understanding critical quality attributes can result in batch failures and regulatory rejection. Each step in this checklist is designed to prevent a specific type of failure.

Core Idea in Plain Language: The Five Gates

Think of the lab-to-market journey as a series of five gates. At each gate, you must demonstrate that your product meets certain criteria before you can pass through to the next stage. The gates are: (1) Concept Validation, (2) Feasibility and IP, (3) Regulatory and Manufacturing Strategy, (4) Clinical or Performance Testing, and (5) Commercial Launch Preparation. Each gate requires a specific set of activities and decisions.

The checklist approach works because it forces you to be explicit about what you know and what you don't. At each gate, you review your data, identify gaps, and decide whether to proceed, pivot, or pause. This is not a rigid waterfall—you can iterate and go back to earlier steps—but it provides a structure that prevents you from skipping critical work.

Gate 1: Concept Validation

Before investing in scale-up or clinical trials, you need to confirm that your product concept is sound. This means demonstrating the mechanism of action in a relevant model, establishing a clear value proposition, and understanding the competitive landscape. For a therapeutic, this might include in vitro and in vivo proof-of-concept. For a diagnostic, it means showing that your test accurately measures what it claims to measure.

Gate 2: Feasibility and IP

Once you have a validated concept, you must ensure that it can be made and that you have the rights to do so. Feasibility includes assessing manufacturability, raw material availability, and cost of goods. Intellectual property (IP) involves filing patent applications, conducting freedom-to-operate searches, and securing licenses for any third-party technologies you rely on.

Gate 3: Regulatory and Manufacturing Strategy

This gate requires a detailed plan for how you will get regulatory approval and how you will produce the product at scale. You need to choose the right regulatory pathway (e.g., 510(k), PMA, BLA, or NDA), identify the key data requirements, and develop a manufacturing process that meets quality standards. This is also the time to start engaging with regulators through pre-submission meetings.

Gate 4: Clinical or Performance Testing

For most products, you will need to generate evidence of safety and efficacy in humans (for drugs and devices) or robust performance data (for diagnostics and tools). This gate covers the design and execution of clinical trials or validation studies, including patient recruitment, data collection, and statistical analysis.

Gate 5: Commercial Launch Preparation

The final gate is about getting the product to market. This includes pricing and reimbursement strategy, sales and distribution channels, marketing materials, and post-market surveillance plans. Many promising products fail here because they underestimated the time and cost of commercial launch.

How It Works Under the Hood: The Decision Framework

Each gate in the checklist is not just a to-do list; it's a decision point. The team must gather specific data, evaluate it against predefined criteria, and make a go/no-go decision. This section explains the mechanics of how to run each gate effectively.

Setting Go/No-Go Criteria

Before entering a gate, define what success looks like. For example, at Gate 1, a go criterion might be: "Achieve at least 50% reduction in tumor volume in the mouse model with acceptable toxicity." At Gate 2, a go criterion might be: "Confirm that the lead compound can be synthesized at >90% purity with a cost of goods under $50 per gram." These criteria should be specific, measurable, and agreed upon by the team.

Data Review and Gap Analysis

At each gate, the team reviews all available data against the criteria. They identify gaps—information that is missing or incomplete. For example, you might have animal efficacy data but lack pharmacokinetic data. The gap analysis leads to a list of experiments or studies that need to be completed before the next gate.

Resource Allocation and Timeline

Based on the gap analysis, the team decides what resources (time, money, personnel) are needed to fill the gaps. This step is critical for budgeting and project planning. A common mistake is to underestimate the time required for regulatory submissions or manufacturing scale-up. The checklist helps by forcing you to think about these tasks early.

Decision and Documentation

After reviewing the data and gap analysis, the team makes a decision: go (proceed to the next gate), no-go (stop the project or pivot), or hold (gather more data). The decision should be documented with rationale. This documentation is invaluable for future reference, especially if the project encounters problems later.

Iteration and Feedback Loops

The checklist is not a one-way street. If you discover a problem at Gate 3, you may need to go back to Gate 2 to refine your IP strategy or rethink your manufacturing approach. The structure allows for iteration while maintaining overall direction.

Worked Example: A Hypothetical Diagnostic Test for Early Cancer Detection

Let's walk through how a team developing a blood-based diagnostic for early-stage pancreatic cancer might use this checklist. The team has a prototype assay that detects a panel of protein biomarkers with high sensitivity in a small retrospective study.

Gate 1: Concept Validation

The team confirms the biomarkers are relevant by testing them in a larger retrospective cohort. They also compare their test's performance to existing methods (e.g., CA19-9). They find that their test has 85% sensitivity and 90% specificity, which is better than current options. They also conduct a market analysis showing that early detection of pancreatic cancer is a significant unmet need. Go decision.

Gate 2: Feasibility and IP

The team files a provisional patent covering the biomarker panel and the assay method. They also conduct a freedom-to-operate search and find that a competitor has a patent on one of the biomarkers, but it expires in two years. They decide to proceed but plan to monitor the patent situation. On the feasibility side, they test the assay on a small number of clinical samples using the intended platform (ELISA) and find that the reagents are stable and reproducible. Cost of goods is estimated at $15 per test. Go decision.

Gate 3: Regulatory and Manufacturing Strategy

The team decides to pursue a 510(k) pathway, as there are predicate devices for cancer biomarker tests. They begin drafting a submission plan, including the necessary analytical validation studies (precision, accuracy, linearity, etc.). They also identify a contract manufacturing organization (CMO) that can produce the assay kits at the required scale. The CMO conducts a feasibility run and confirms the process is scalable. However, the team discovers that the stability of one antibody reagent is poor, requiring a reformulation. They put the project on hold for three months to solve the stability issue. After reformulation, they proceed. Go decision.

Gate 4: Clinical Performance Testing

The team designs a prospective clinical study with 500 patients (250 cancer, 250 controls) to validate the test. They recruit from multiple sites to ensure diversity. The study takes 18 months. The results show 82% sensitivity and 88% specificity, slightly lower than the retrospective data but still acceptable. They also collect data on reproducibility across sites. Go decision.

Gate 5: Commercial Launch Preparation

The team works on pricing and reimbursement. They engage with payers early and learn that the test needs to demonstrate cost-effectiveness to be covered. They develop a health-economic model showing that early detection reduces overall treatment costs. They also build a sales team and create marketing materials for oncologists and primary care physicians. The product launches on schedule, and within the first year, it is adopted by several large health systems.

Edge Cases and Exceptions

The five-gate checklist works well for many biotech products, but it is not one-size-fits-all. Here are some situations where the standard approach may need adjustment.

Orphan Drugs and Rare Diseases

For products targeting small patient populations, clinical trial design is different. You may need to use adaptive trial designs, surrogate endpoints, or real-world evidence. The regulatory pathway is often expedited (e.g., orphan drug designation, breakthrough therapy). In these cases, the checklist still applies, but the criteria at each gate need to be tailored to the specific regulatory and commercial context.

Platform Technologies

If your product is a platform (e.g., a gene therapy vector or a cell therapy process), you may need to run multiple parallel product tracks. The checklist should be applied to each product candidate, but you can reuse some data (e.g., manufacturing process validation) across products. Be careful not to assume that what works for one product works for all; each indication may have unique requirements.

Diagnostics vs. Therapeutics

Diagnostics generally have a faster path to market than therapeutics, but they face different challenges. Reimbursement is often a bigger hurdle for diagnostics, and clinical utility studies (showing that the test improves patient outcomes) are increasingly required. The checklist should be adapted to include a strong focus on health economics and payer engagement from Gate 2 onward.

Academic Spin-Outs

Teams coming from academia often underestimate the business and regulatory aspects. They may have strong science but lack experience in manufacturing, IP strategy, or regulatory affairs. In such cases, it's crucial to bring in experienced advisors or partners early. The checklist can help identify these gaps, but the team must be willing to seek external help.

When the Science Changes

Sometimes new data forces a major pivot. For instance, a competitor may publish a paper that invalidates your mechanism, or a clinical trial may reveal unexpected toxicity. The checklist should include a regular review of the external landscape. If the science changes, you may need to go back to Gate 1 or stop the project altogether.

Limits of the Approach

No checklist can guarantee success in biotech. The five-gate model has several limitations that teams should be aware of.

It Cannot Predict the Future

The checklist is based on current knowledge and assumptions. It cannot account for unexpected regulatory changes, market shifts, or scientific breakthroughs that render your product obsolete. Teams must remain flexible and willing to adapt.

It Requires Honest Self-Assessment

The gate decisions are only as good as the data and the team's willingness to be objective. There is a strong temptation to downplay risks or ignore negative data to keep a project alive. The checklist works best when there is a culture of transparency and a willingness to kill projects that don't meet criteria.

It Can Be Time-Consuming

Running each gate rigorously takes time and resources. In a fast-moving field, you may need to make decisions with incomplete data. The checklist should be used as a guide, not a straitjacket. Sometimes you need to proceed with a "conditional go" and gather data in parallel.

It Does Not Cover All Aspects

The checklist focuses on the product development pathway, but it does not address organizational issues like team dynamics, funding strategy, or partnership negotiations. These are equally important and should be managed separately.

It Is Not a Substitute for Expertise

Finally, the checklist is a tool, not a replacement for experienced professionals. Regulatory affairs, clinical development, manufacturing, and commercial strategy each require deep expertise. The checklist helps you know what questions to ask, but you still need people who know the answers.

Despite these limitations, the five-step checklist is a powerful framework for bringing biotech products to market. It imposes discipline, surfaces risks early, and helps teams allocate resources effectively. To get started, print out the five gates, define your go/no-go criteria, and schedule your first gate review. Then, commit to being honest about what you find. The market—and the patients who need your product—will thank you.